OBJECTIVE: To determine willingness of health professionals to adopt new interventions for treating sexual partners of women with chlamydia. DESIGN: Anonymous, self-administered questionnaires of doctors, practice nurses and community pharmacists regarding novel testing/treatment options for partners of women with chlamydia. SETTING: Local (Scotland) and national (UK) clinical meetings in reproductive health, and community pharmacy (Lothian). POPULATION: Doctors (general practice, gynaecology, family planning) and practice nurses who were delegates at selected meetings in reproductive health and community pharmacists attending pharmacy meetings. METHODS: Doctors and nurses were invited to complete a questionnaire indicating their preferred strategy for testing/treating sexual partners of women with chlamydia if given choice of partner notification, postal testing kit (PTK), patient delivered partner medication (PDPM) with azithromycin or combined PDPM and PTK. Community pharmacists were invited to complete a questionnaire regarding their willingness to introduce chlamydia testing and treatment services. MAIN OUTCOME MEASURES: Reported preferences of doctors and nurses for partner testing/treatment strategies and willingness of pharmacists to offer new services. RESULTS: Questionnaires were completed by 211 doctors, 73 practice nurses and 50 pharmacists. The most popular choice of doctors (30%) and nurses (23%) was a combination of PDPM with PTK, with partner notification the least popular (8 and 3%, respectively). One in four doctors had previously used PDPM for treating partners. Most pharmacists were willing to supply free PTKs (98%), offer testing (75%) and treatment services (100%) and give women PDPM for partners (80%). CONCLUSION: Relevant health professionals, who are increasingly involved in managing chlamydia, are largely in favour of introducing new strategies for treating sexual partners.
OBJECTIVE: To determine willingness of health professionals to adopt new interventions for treating sexual partners of women with chlamydia. DESIGN: Anonymous, self-administered questionnaires of doctors, practice nurses and community pharmacists regarding novel testing/treatment options for partners of women with chlamydia. SETTING: Local (Scotland) and national (UK) clinical meetings in reproductive health, and community pharmacy (Lothian). POPULATION: Doctors (general practice, gynaecology, family planning) and practice nurses who were delegates at selected meetings in reproductive health and community pharmacists attending pharmacy meetings. METHODS: Doctors and nurses were invited to complete a questionnaire indicating their preferred strategy for testing/treating sexual partners of women with chlamydia if given choice of partner notification, postal testing kit (PTK), patient delivered partner medication (PDPM) with azithromycin or combined PDPM and PTK. Community pharmacists were invited to complete a questionnaire regarding their willingness to introduce chlamydia testing and treatment services. MAIN OUTCOME MEASURES: Reported preferences of doctors and nurses for partner testing/treatment strategies and willingness of pharmacists to offer new services. RESULTS: Questionnaires were completed by 211 doctors, 73 practice nurses and 50 pharmacists. The most popular choice of doctors (30%) and nurses (23%) was a combination of PDPM with PTK, with partner notification the least popular (8 and 3%, respectively). One in four doctors had previously used PDPM for treating partners. Most pharmacists were willing to supply free PTKs (98%), offer testing (75%) and treatment services (100%) and give women PDPM for partners (80%). CONCLUSION: Relevant health professionals, who are increasingly involved in managing chlamydia, are largely in favour of introducing new strategies for treating sexual partners.
Authors: Natasha L Pavlin; Rhian M Parker; Anna K Piggin; Carol A Hopkins; Meredith J Temple-Smith; Christopher K Fairley; Jane E Tomnay; Francis J Bowden; Darren B Russell; Jane S Hocking; Marian K Pitts; Marcus Y Chen Journal: BMC Infect Dis Date: 2010-09-20 Impact factor: 3.090